timothy sykes logo
LABT Slides As Biotech Traders Gauge Cash Burn Risk Thumbnail
G Google News

LABT Slides As Biotech Traders Gauge Cash Burn Risk

JACK KELLOGG•UPDATED MAY. 2, 2026, 10:06 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Lakewood-Amedex Biotherapeutics Inc. stocks have been trading up by 19.18 percent on strong sentiment toward its latest therapeutic developments.

Candlestick Chart

Weekly Update Apr 27 – May 01, 2026: On Saturday, May 02, 2026 Lakewood-Amedex Biotherapeutics Inc. stock [NASDAQ: LABT] is trending up by 19.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

LABT is a micro-cap, pre-revenue lab tools/biotech platform with highly stressed fundamentals. The latest filing shows no revenue, negative EBITDA of roughly -$0.68M and net loss of -$0.74M for the quarter, with operating cash flow and free cash flow both at -$0.42M. Cash is only $0.24M against total liabilities of $2.45M, producing negative equity of -$1.96M and deeply negative retained earnings, implying acute dilution and/or restructuring risk over the next 12 months.

Technically, LABT is in a short-term downtrend after a failed attempt to hold above $4.20. The weekly sequence from 4.20 high to a 2.77 low, followed by a weak bounce to 3.17, points to aggressive supply on every rally. Intraday 5-minute candles (with expanding ranges and fading bounces) confirm distribution on elevated volume near $3.70–$3.90. The key actionable level is $3.20: below it, momentum shorts are favored with a tactical cover zone near $2.70.

With no meaningful news flow, LABT trades purely as a speculative vehicle, lagging broader Healthcare and Biotechnology & Life Sciences indices on risk-adjusted returns and fundamental quality. Peers generally maintain positive equity and longer cash runways; LABT does not. Near term, key resistance stands at $3.80–$4.00, while support rests at $2.60–$2.80, with a downside break likely if financing terms disappoint. The decisive stance: avoid for investment, trade only tactically with tight risk controls.

Quick Financial Overview

Lakewood-Amedex Biotherapeutics Inc. (LABT) shows a textbook picture of a speculative biotech with sharp price swings and fragile fundamentals. On the weekly chart, LABT dropped from above $4.00 to a recent close near $3.17 after failing to hold a bounce, a clear sign that sellers are still in control. That move reflects a steady series of lower closes, which often means momentum traders are stepping back or locking in profits rather than pressing new longs.

The intraday snapshot backs this up. LABT traded in a very wide band, spiking toward $4.61 before sliding to around $3.13 and settling near $3.43. That kind of intraday range tells traders two things: liquidity can be thin, and stop placement matters. Breakouts can reverse quickly, so any long or short bias needs defined risk and smaller size than a highly liquid large cap.

Financially, LABT is burning cash and running a heavily negative equity position. Net income for the latest quarter came in around -$0.74M, with operating cash flow also roughly -$0.42M, shrinking cash on hand to about $0.24M. Total liabilities of roughly $2.45M and stockholders’ equity near -$1.96M signal a balance sheet under strain, with working capital deeply negative. For traders, that combination often points to potential capital raises, reverse splits, or restructuring risk down the line — all of which can hit the share price hard.

More Breaking News

Conclusion

Lakewood-Amedex Biotherapeutics Inc. sits in a tough spot where speculative price swings collide with weak fundamentals. On the tape, LABT has moved from a push above $4.00 into the low $3.00s, showing that recent strength was sold into rather than accumulated. The intraday range between roughly $4.61 and $3.13 underlines that this is a fast-moving name where slippage and whipsaws are part of the game. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”, and that mindset is particularly relevant in a ticker like LABT, where discipline and trade management can matter more than the story.

From a financial standpoint, ongoing operating losses, negative equity, and a thin cash cushion mean LABT carries high balance-sheet risk. Traders need to recognize that any sharp rally can be met by financing moves, while further selling could accelerate if confidence in the company’s runway fades. This is the definition of a high-risk, high-volatility biotech trade, best approached with clear levels and strict risk controls.

For short-term traders, LABT’s key focus points are whether the low $3.00 area holds on pullbacks and how price behaves on any retest of the $4.00 zone. Until the capital structure improves, this remains a tactical trading vehicle, not a comfort-hold. As I tell my students: “In names like LABT, the edge doesn’t come from believing the story — it comes from respecting the risk, reading the chart, and letting the price action, not hope, drive your decisions.””,”scores”:{“risk-level”:”9″},”trade”:”false

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading LABT

Millionaire's
POV on LABT

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”